Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
28
PHAT Quote, Financials, Valuation and Earnings
Last price:
$11.44
Seasonality move
:
-6.87%
Day range:
$11.44 - $12.33
52-week range:
$2.21 - $18.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.77x
P/B ratio:
--
Volume:
2M
Avg. volume:
1.1M
1-year change:
107.61%
Market cap:
$894M
Revenue:
$175.1M
EPS (TTM):
-$3.05
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PHAT
Phathom Pharmaceuticals, Inc.
|
$57.4M | -$0.19 | 106.56% | -84.92% | $23.50 |
|
LGND
Ligand Pharmaceuticals, Inc.
|
$55.6M | $1.50 | 32.03% | -74.47% | $244.56 |
|
MNKD
MannKind Corp.
|
$99.9M | $0.03 | 36.67% | -59.34% | $7.72 |
|
OCGN
Ocugen, Inc.
|
$860K | -$0.06 | -66.24% | -14.07% | $9.00 |
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
$56.2M | -$0.78 | 72.09% | -0.07% | $139.67 |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$59.3M | -- | 8.46% | -- | $14.88 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PHAT
Phathom Pharmaceuticals, Inc.
|
$11.46 | $23.50 | $894M | -- | $0.00 | 0% | 4.77x |
|
LGND
Ligand Pharmaceuticals, Inc.
|
$202.55 | $244.56 | $4B | 34.71x | $0.00 | 0% | 15.28x |
|
MNKD
MannKind Corp.
|
$3.04 | $7.72 | $932M | 180.65x | $0.00 | 0% | 2.72x |
|
OCGN
Ocugen, Inc.
|
$1.94 | $9.00 | $635M | -- | $0.00 | 0% | 106.48x |
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
$94.94 | $139.67 | $6.3B | -- | $0.00 | 0% | 32.51x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$8.17 | $14.88 | $482.9M | -- | $0.00 | 0% | 2.23x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PHAT
Phathom Pharmaceuticals, Inc.
|
390.17% | 4.230 | 49.92% | 1.58x |
|
LGND
Ligand Pharmaceuticals, Inc.
|
30.74% | 1.421 | 12.13% | 21.18x |
|
MNKD
MannKind Corp.
|
112.08% | 0.597 | 27.19% | 1.23x |
|
OCGN
Ocugen, Inc.
|
90.32% | 1.352 | 6.48% | 1.60x |
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
63.61% | 0.368 | 3.4% | 3.92x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
3.72% | -1.020 | 2.42% | 2.24x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PHAT
Phathom Pharmaceuticals, Inc.
|
$49.9M | -$5.9M | -109.76% | -- | -10.3% | -$5.1M |
|
LGND
Ligand Pharmaceuticals, Inc.
|
$48.6M | $20M | 11.65% | 14.07% | 33.59% | $45.3M |
|
MNKD
MannKind Corp.
|
$78.3M | -$1.7M | 3.35% | -- | -1.49% | -$9.4M |
|
OCGN
Ocugen, Inc.
|
$802K | -$17.6M | -139.38% | -345.08% | -1005.99% | -$13M |
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
$52.5M | -$47.1M | -61.67% | -310.34% | -82.2% | -$26.3M |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$49.6M | -$40.4M | -46.15% | -47.32% | -70.53% | -$29.5M |
Phathom Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns PHAT or LGND?
Ligand Pharmaceuticals, Inc. has a net margin of -36.73% compared to Phathom Pharmaceuticals, Inc.'s net margin of 75.06%. Phathom Pharmaceuticals, Inc.'s return on equity of -- beat Ligand Pharmaceuticals, Inc.'s return on equity of 14.07%.
Company Gross Margin Earnings Per Share Invested Capital PHATPhathom Pharmaceuticals, Inc.86.72% -$0.29 $151M LGNDLigand Pharmaceuticals, Inc.81.42% $2.12 $1.5B -
What do Analysts Say About PHAT or LGND?
Phathom Pharmaceuticals, Inc. has a consensus price target of $23.50, signalling upside risk potential of 105.06%. On the other hand Ligand Pharmaceuticals, Inc. has an analysts' consensus of $244.56 which suggests that it could grow by 20.74%. Given that Phathom Pharmaceuticals, Inc. has higher upside potential than Ligand Pharmaceuticals, Inc., analysts believe Phathom Pharmaceuticals, Inc. is more attractive than Ligand Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PHATPhathom Pharmaceuticals, Inc.8 2 0 LGNDLigand Pharmaceuticals, Inc.6 0 0 -
Is PHAT or LGND More Risky?
Phathom Pharmaceuticals, Inc. has a beta of 0.509, which suggesting that the stock is 49.056% less volatile than S&P 500. In comparison Ligand Pharmaceuticals, Inc. has a beta of 1.207, suggesting its more volatile than the S&P 500 by 20.687%.
-
Which is a Better Dividend Stock PHAT or LGND?
Phathom Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ligand Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phathom Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ligand Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHAT or LGND?
Phathom Pharmaceuticals, Inc. quarterly revenues are $57.6M, which are smaller than Ligand Pharmaceuticals, Inc. quarterly revenues of $59.7M. Phathom Pharmaceuticals, Inc.'s net income of -$21.1M is lower than Ligand Pharmaceuticals, Inc.'s net income of $44.8M. Notably, Phathom Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Ligand Pharmaceuticals, Inc.'s PE ratio is 34.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals, Inc. is 4.77x versus 15.28x for Ligand Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHATPhathom Pharmaceuticals, Inc.4.77x -- $57.6M -$21.1M LGNDLigand Pharmaceuticals, Inc.15.28x 34.71x $59.7M $44.8M
-
Which has Higher Returns PHAT or MNKD?
MannKind Corp. has a net margin of -36.73% compared to Phathom Pharmaceuticals, Inc.'s net margin of -14.25%. Phathom Pharmaceuticals, Inc.'s return on equity of -- beat MannKind Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PHATPhathom Pharmaceuticals, Inc.86.72% -$0.29 $151M MNKDMannKind Corp.69.95% -$0.05 $422.4M -
What do Analysts Say About PHAT or MNKD?
Phathom Pharmaceuticals, Inc. has a consensus price target of $23.50, signalling upside risk potential of 105.06%. On the other hand MannKind Corp. has an analysts' consensus of $7.72 which suggests that it could grow by 154.44%. Given that MannKind Corp. has higher upside potential than Phathom Pharmaceuticals, Inc., analysts believe MannKind Corp. is more attractive than Phathom Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PHATPhathom Pharmaceuticals, Inc.8 2 0 MNKDMannKind Corp.8 1 0 -
Is PHAT or MNKD More Risky?
Phathom Pharmaceuticals, Inc. has a beta of 0.509, which suggesting that the stock is 49.056% less volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.834, suggesting its less volatile than the S&P 500 by 16.605%.
-
Which is a Better Dividend Stock PHAT or MNKD?
Phathom Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phathom Pharmaceuticals, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHAT or MNKD?
Phathom Pharmaceuticals, Inc. quarterly revenues are $57.6M, which are smaller than MannKind Corp. quarterly revenues of $112M. Phathom Pharmaceuticals, Inc.'s net income of -$21.1M is lower than MannKind Corp.'s net income of -$15.9M. Notably, Phathom Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 180.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals, Inc. is 4.77x versus 2.72x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHATPhathom Pharmaceuticals, Inc.4.77x -- $57.6M -$21.1M MNKDMannKind Corp.2.72x 180.65x $112M -$15.9M
-
Which has Higher Returns PHAT or OCGN?
Ocugen, Inc. has a net margin of -36.73% compared to Phathom Pharmaceuticals, Inc.'s net margin of -1144.46%. Phathom Pharmaceuticals, Inc.'s return on equity of -- beat Ocugen, Inc.'s return on equity of -345.08%.
Company Gross Margin Earnings Per Share Invested Capital PHATPhathom Pharmaceuticals, Inc.86.72% -$0.29 $151M OCGNOcugen, Inc.45.78% -$0.07 $36.5M -
What do Analysts Say About PHAT or OCGN?
Phathom Pharmaceuticals, Inc. has a consensus price target of $23.50, signalling upside risk potential of 105.06%. On the other hand Ocugen, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 363.92%. Given that Ocugen, Inc. has higher upside potential than Phathom Pharmaceuticals, Inc., analysts believe Ocugen, Inc. is more attractive than Phathom Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PHATPhathom Pharmaceuticals, Inc.8 2 0 OCGNOcugen, Inc.4 0 0 -
Is PHAT or OCGN More Risky?
Phathom Pharmaceuticals, Inc. has a beta of 0.509, which suggesting that the stock is 49.056% less volatile than S&P 500. In comparison Ocugen, Inc. has a beta of 2.750, suggesting its more volatile than the S&P 500 by 175.048%.
-
Which is a Better Dividend Stock PHAT or OCGN?
Phathom Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phathom Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ocugen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHAT or OCGN?
Phathom Pharmaceuticals, Inc. quarterly revenues are $57.6M, which are larger than Ocugen, Inc. quarterly revenues of $1.8M. Phathom Pharmaceuticals, Inc.'s net income of -$21.1M is lower than Ocugen, Inc.'s net income of -$20.1M. Notably, Phathom Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Ocugen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals, Inc. is 4.77x versus 106.48x for Ocugen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHATPhathom Pharmaceuticals, Inc.4.77x -- $57.6M -$21.1M OCGNOcugen, Inc.106.48x -- $1.8M -$20.1M
-
Which has Higher Returns PHAT or RYTM?
Rhythm Pharmaceuticals, Inc. has a net margin of -36.73% compared to Phathom Pharmaceuticals, Inc.'s net margin of -82.97%. Phathom Pharmaceuticals, Inc.'s return on equity of -- beat Rhythm Pharmaceuticals, Inc.'s return on equity of -310.34%.
Company Gross Margin Earnings Per Share Invested Capital PHATPhathom Pharmaceuticals, Inc.86.72% -$0.29 $151M RYTMRhythm Pharmaceuticals, Inc.91.61% -$0.73 $382.2M -
What do Analysts Say About PHAT or RYTM?
Phathom Pharmaceuticals, Inc. has a consensus price target of $23.50, signalling upside risk potential of 105.06%. On the other hand Rhythm Pharmaceuticals, Inc. has an analysts' consensus of $139.67 which suggests that it could grow by 47.11%. Given that Phathom Pharmaceuticals, Inc. has higher upside potential than Rhythm Pharmaceuticals, Inc., analysts believe Phathom Pharmaceuticals, Inc. is more attractive than Rhythm Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PHATPhathom Pharmaceuticals, Inc.8 2 0 RYTMRhythm Pharmaceuticals, Inc.11 1 0 -
Is PHAT or RYTM More Risky?
Phathom Pharmaceuticals, Inc. has a beta of 0.509, which suggesting that the stock is 49.056% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals, Inc. has a beta of 2.058, suggesting its more volatile than the S&P 500 by 105.795%.
-
Which is a Better Dividend Stock PHAT or RYTM?
Phathom Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phathom Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Rhythm Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHAT or RYTM?
Phathom Pharmaceuticals, Inc. quarterly revenues are $57.6M, which are larger than Rhythm Pharmaceuticals, Inc. quarterly revenues of $57.3M. Phathom Pharmaceuticals, Inc.'s net income of -$21.1M is higher than Rhythm Pharmaceuticals, Inc.'s net income of -$47.5M. Notably, Phathom Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Rhythm Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals, Inc. is 4.77x versus 32.51x for Rhythm Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHATPhathom Pharmaceuticals, Inc.4.77x -- $57.6M -$21.1M RYTMRhythm Pharmaceuticals, Inc.32.51x -- $57.3M -$47.5M
-
Which has Higher Returns PHAT or VNDA?
Vanda Pharmaceuticals, Inc. has a net margin of -36.73% compared to Phathom Pharmaceuticals, Inc.'s net margin of -246.76%. Phathom Pharmaceuticals, Inc.'s return on equity of -- beat Vanda Pharmaceuticals, Inc.'s return on equity of -47.32%.
Company Gross Margin Earnings Per Share Invested Capital PHATPhathom Pharmaceuticals, Inc.86.72% -$0.29 $151M VNDAVanda Pharmaceuticals, Inc.86.65% -$2.39 $339.8M -
What do Analysts Say About PHAT or VNDA?
Phathom Pharmaceuticals, Inc. has a consensus price target of $23.50, signalling upside risk potential of 105.06%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $14.88 which suggests that it could grow by 82.07%. Given that Phathom Pharmaceuticals, Inc. has higher upside potential than Vanda Pharmaceuticals, Inc., analysts believe Phathom Pharmaceuticals, Inc. is more attractive than Vanda Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PHATPhathom Pharmaceuticals, Inc.8 2 0 VNDAVanda Pharmaceuticals, Inc.3 1 0 -
Is PHAT or VNDA More Risky?
Phathom Pharmaceuticals, Inc. has a beta of 0.509, which suggesting that the stock is 49.056% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.303%.
-
Which is a Better Dividend Stock PHAT or VNDA?
Phathom Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phathom Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHAT or VNDA?
Phathom Pharmaceuticals, Inc. quarterly revenues are $57.6M, which are larger than Vanda Pharmaceuticals, Inc. quarterly revenues of $57.2M. Phathom Pharmaceuticals, Inc.'s net income of -$21.1M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$141.2M. Notably, Phathom Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals, Inc. is 4.77x versus 2.23x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHATPhathom Pharmaceuticals, Inc.4.77x -- $57.6M -$21.1M VNDAVanda Pharmaceuticals, Inc.2.23x -- $57.2M -$141.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
50
AXTI alert for Mar 3
AXT, Inc. [AXTI] is down 13.86% over the past day.
Buy
53
AAOI alert for Mar 3
Applied Optoelectronics, Inc. [AAOI] is down 7.76% over the past day.
Sell
32
TPB alert for Mar 3
Turning Point Brands, Inc. [TPB] is down 3.24% over the past day.
